Risk‐Benefit Value of Inhaled Glucocorticoids: A Pharmacokinetic/ Pharmacodynamic Perspective
- 1 January 2004
- journal article
- review article
- Published by Wiley in The Journal of Clinical Pharmacology
- Vol. 44 (1), 37-47
- https://doi.org/10.1177/0091270003260334
Abstract
Inhaled glucocorticoids induce therapeutic and adverse systemic effects via the same types of receptors. Analysis of the pharmacokinetic/pharmacodynamic parameters of inhaled glucocorticoids generates a risk-benefit value (RBV). Targeted efficacy with minimal adverse effects helps to quantify an appropriate RBV. High lung deposition/targeting, high receptor binding, longer pulmonary retention, and high lipid conjugation are among the pharmacokinetic parameters to be considered for improved efficacy of the compound. Low or negligible oral bioavailability, small particle size and inactive drug at the oropharynx, high plasma protein binding, rapid metabolism, high clearance, and lower systemic concentrations are associated with low risks for adverse effects. Inhaled glucocorticoid potency is enhanced by solution inhalers, which result in higher pulmonary deposition and minimize local adverse effects. These properties, among others, determine the efficacy and safety of inhaled glucocorticoids. Currently available inhaled glucocorticoids do not provide the complete pharmacokinetic/pharmacodynamic parameters to optimize RBV, leaving room for improvement in the development of future agents.Keywords
This publication has 56 references indexed in Scilit:
- Single‐Dose and Steady‐State Pharmacokinetic and Pharmacodynamic Evaluation of Therapeutically Clinically Equivalent Doses of Inhaled Fluticasone Propionate and Budesonide, Given as Diskus® or Turbohaler® Dry‐Powder Inhalers to Healthy SubjectsThe Journal of Clinical Pharmacology, 2001
- Effective control of asthma with hydrofluoroalkane flunisolide delivered as an extrafine aerosol in asthma patientsAnnals of Allergy, Asthma & Immunology, 2001
- Deposition and Pharmacokinetics of Flunisolide Delivered from Pressurized Inhalers Containing Non-CFC and CFC PropellantsJournal of Aerosol Medicine, 2001
- Long-term safety and efficacy of a chlorofluorocarbon-free beclomethasone dipropionate extrafine aerosolAnnals of Allergy, Asthma & Immunology, 2001
- Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with severe persistent asthmaJournal of Allergy and Clinical Immunology, 2000
- Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthmaJournal of Allergy and Clinical Immunology, 2000
- Pharmacokinetics of flunisolide administered via metered dose inhaler with and without a spacer device and following oral administrationAnnals of Allergy, Asthma & Immunology, 2000
- Comparative Efficacy and Safety of Twice Daily Fluticasone Propionate Powder Versus Placebo in the Treatment of Moderate AsthmaAnnals of Allergy, Asthma & Immunology, 1997
- Pharmacokinetics of Triamcinolone Acetonide After Intravenous, Oral, and Inhaled AdministrationThe Journal of Clinical Pharmacology, 1995
- Fluticasone propionate aerosol for the treatment of adults with mild to moderate asthmaJournal of Allergy and Clinical Immunology, 1994